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Abstract
Background: Infection is a complication of TRUS prostate biopsy, despite the use of antimicrobial prophylaxis.
Worryingly the rate of infectious complications following TRUS biopsy has been shown to be increasing. We aimed
to determine the rate, severity, risk factors, standard patterns of care and microbiology resistance profiles associated
with TRUS biopsy sepsis.
Methods: A retrospective case–control study was conducted. Using electronic coding all patients who presented to
Cabrini Hospital with sepsis following a TRUS biopsy from 2009 to 2013 were identified. Validated cases were
matched to controls in a ratio of 1:3. Eligible controls were required to have undergone a TRUS biopsy at the
same surgical institution as the case and in the closest period of time. Demographic, procedural and patient
related data-points were recorded for all patients using hospital and urologist records. Univariate logistic
regression models were constructed and used to determine risk factors associated with infection.
Results: 71 cases developed sepsis following TRUS biopsy and were matched to 213 controls. The average rate of
sepsis over the 5-year study period was 1.5 %. A SOFA score ≥ 2 was identified in 28 % of cases. We found a high
prevalence of antimicrobial resistant E. coli, with 61 % of blood culture isolates classified as Multidrug resistant
organisms. Eight different prophylactic antimicrobial regimens were identified with 33 % of cases receiving
ineffective antimicrobial prophylaxis. Statistically significant risk factors included previous antimicrobial use and
prior international travel within the six months prior to biopsy.
Conclusions: TRUS biopsy is an elective procedure and as such needs to be associated with minimal morbidity.
The patterns of care surrounding periprocedural variables for TRUS biopsies were non-uniform and diverse. A
wide variety of different prophylaxis regimens and bowel preparation routines were recorded. Patients with risk
factors for sepsis may represent a better target population for intervention with alternative preventative
strategies. Alternative preventative options include augmented prophylaxis, tailored prophylaxis or the TP biopsy
approach either as a first line biopsy modality or based on epidemiological risk factors.
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Background
The diagnosis of prostate cancer is confirmed by pros-
tate biopsy. Transrectal ultrasound-guided (TRUS) bi-
opsy is the most common method of obtaining prostate
tissue for analysis [1]. TRUS biopsies are typically con-
sidered to be a well-tolerated outpatient procedure
however complications are well recognized [2]. Current
practice guidelines unanimously recommend the use of
antimicrobial prophylaxis prior to a TRUS biopsy,
which has been shown to significantly decrease the risk
of post-biopsy infectious complications [3–5]. However
infectious complications may still develop with the re-
ported rate of sepsis ranging from 0.6-5.7 % in contem-
porary studies [6, 7] with evidence of an increasing
trend [8, 9].
The proposed pathophysiology of post-biopsy infection
most likely results from the transrectal passage of the bi-
opsy needle. This approach allows for the inoculation of
bacteria from the rectal mucosa directly into the prostate,
blood vessels or urinary tract [10, 11]. The best evidence
suggests that the presence of endogenous antimicrobial-
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resistant bacteria is a significant risk factor for infectious
complications [12–15]. In particular, Steensels et al. found
that the presence of endogenous fluoroquinolone-resistant
bacteria in men undergoing a TRUS biopsy was a risk
factor for developing post-biopsy infectious complications
[16]. The risk of acquiring endogenous antimicrobial-
resistant bacteria may be increased by several factors such
as antimicrobial use [17–20] or international travel prior
to TRUS biopsy [20, 21].
Other risk factors for developing sepsis following
TRUS biopsy can be categorized as patient-related or
procedural. No definitive patient or procedure-specific
risk factors have been identified, despite analysis of
patient co-morbidities [9, 22, 23], the use of pre-biopsy
enema [6, 24] or the number of cores taken during the
procedure [25].
In the present study we aimed to determine the rate,
severity, risk factors and microbiology resistance pat-
terns associated with TRUS biopsy sepsis. As well as the
standard patterns of care surrounding TRUS prostate
biopsy.
Methods
The population was defined as patients undergoing a
TRUS prostate biopsy by a urologist associated with
Cabrini Hospital, a private 700-bed metropolitan hospital
in Melbourne. This included patients who had their TRUS
biopsy at smaller neighbouring institutions, but in the
event of complications were instructed to present to
Cabrini Hospital’s Emergency Department. Neighbour-
ing institutions included Linacre Private Hospital, Masada
Private Hospital and the Avenue Hospital. All biopsies
were completed using a standard ultrasound and biopsy
probe with patients receiving prophylactic antimicrobials
and intravenous sedation prior to their procedure. A case
was defined as a patient who presented to hospital with
sepsis due to suspected or confirmed infection related to
the genitourinary tract or where no other focus of infec-
tion was clinically evident within 14 days of undergoing a
TRUS biopsy from 2009 until 2013. Sepsis was defined
according to the ACCP/SCCM (1991) criteria as a sys-
temic inflammatory response syndrome in the presence of
an infective process [26]. Patients were excluded if they
underwent TRUS biopsy at a non-participating institution.
Cases were identified via an electronic search of the
Cabrini Health data warehouse using Medicare Benefit
Schedule (MBS) codes for TRUS biopsy and International
Classification of Disease and Related Health Problems,
Tenth Revision, Australian Modification (ICD-10-AM)
diagnosis codes for infective complications. These codes
were used to screen for sepsis, which was then confirmed
by a review of the patients’ medical records. Confirmed
cases that underwent their TRUS biopsy at a participating
institution were matched to three control patients. Eligible
controls were the next patients that underwent TRUS
biopsy at the same institution as the case but whom did
not develop infectious complications.
Patient data, including demographic, procedural and
patient-related factors were collected on a standardized
form using hospital and urologist records. Where the
procedure was performed at another institution, proced-
ural data was extracted from urologists’ medical records.
A history of travel was defined as international travel
within six months prior to biopsy. Antimicrobial use was
defined as oral or intravenous antimicrobial therapy
within the six months preceding biopsy. If no history
was documented, it was assumed the patient had not
travelled or taken antimicrobials. We used a modified
Sequential Organ Failure Assessment Score (SOFA) to
determine the severity of illness. The SOFA score is a
standardised assessment tool used to determine the de-
gree of sepsis related organ dysfunction. It is calculated
from the total sum of six organ system categories, each
graded from 0 to 4 based on predefined measurement
values. As many patients did not have an arterial blood
gas, we used arterial oxygen saturation measured by a
pulse oximeter (SpO2) as a surrogate marker for partial
pressure of arterial oxygen (PaO2) [27].
To define risk factors associated with infection, we
constructed univariate conditional logistic regression
models, which accounted for the matched nature of the
control selection. A multiple variable analysis was not
performed due to the relatively low proportion of
patients with any one exposure (and therefore limited
statistical power) and the likelihood of co-linearity be-
tween exposures. We defined statistical significance as
p < 0.05. As this was an exploratory study, we did not
adjust for multiple hypothesis testing. Ethics approval
was obtained from the Cabrini Human Research Ethics
Committee.
Results
Over the five-year study period, 71 patients required ad-
mission to Cabrini Hospital for sepsis following TRUS bi-
opsy and were matched to 219 controls. The mean
proportion of patients with sepsis across the five-year
study period was 1.5 %, with the lowest rate of 0.6 %
reported in 2011 and the highest rate of 2.9 % reported in
2013. No statistically significant difference regarding the
rate of sepsis over the study period was noted (p = 0.091).
The mean duration of admission was 4.5 days (median
4 days, IQR 3,5 days, range 1–14 days). Of the 60
(76.9 %) cases where data was available to assess a SOFA
score, 43 (71.7 %) patients had a SOFA score ≤1, 10
(16.7 %) patients had a score of two, 4 (6.7 %) had a
SOFA score of three and 3 (5 %) patients had a SOFA
score ≥4.
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Urine culture results were available for 66 patients.
Culture results were positive for 28 (42.4 %) patients.
Isolated organisms included 27 Escherichia coli (96.4 %)
and one Acinetobacter spp. (3.6 %). Of all urine isolates,
22 (78.6 %) were resistant to more than one antimicro-
bial agent. Blood culture results were available for 65
patients. Culture results were positive for 36 (55.4 %) pa-
tients. The organisms isolated were E. coli 34 (94.4 %),
Streptococcus pneumoniae 1(2.9 %) and Bacteroides
uniformis 1(2.9 %). Of all blood isolates 28 (77.7 %)
were resistant to more than one antimicrobial agent
(Table 1).
Patient risk factors that were found to be significantly
associated with the development of sepsis following
TRUS biopsy included a history of international travel
or recent antimicrobial use in the six months prior to a
patient’s biopsy (Table 2). Other variables such as pa-
tient comorbidities, recent hospitalization, age or being
a hospital employee were not significantly associated
with sepsis.
The number of biopsy cores most commonly taken
was 14 [Range: 7,22]. More than 12 cores were taken in
63 (88.7 %) case cohort patients and in 202 (94.8 %) of
control cohort patients. Patients who did not develop
sepsis were significantly more likely to have had more
than 12 biopsy cores taken (OR 0.37, 95 % CI 0.14, 0.95,
p = 0.04). Other procedural variables such as the use of a
pre-biopsy enema, prior TRUS biopsy, prostate volume
or biopsy result were not shown to be significantly asso-
ciated with infection.
All patients in this study received antimicrobial
prophylaxis. Over the course of the study eight different
antimicrobial regimens were identified (Table 3). Seven
of the identified regimens included the use of a fluoro-
quinolone antimicrobial and this accounted for 282
(99.3 %) men. The most common prophylaxis regimen
was the use of a fluoroquinolone agent alone, followed
by a fluoroquinolone antimicrobial in combination with
a penicillin antimicrobial. All prophylactic regimens were
distributed equally across the study period. This study
found that the addition of a penicillin antimicrobial
(amoxicillin) to standard fluoroquinolone prophylaxis re-
sulted in a reduced risk of developing sepsis (OR 0.42,
95 % CI 0.18, 0.98, p = 0.05). However, when this risk was
calculated without carbapenem co-administration, 26.8 %
of cases and 31.5 % of controls developed sepsis suggest-
ing pencillins were not effective. There was also shown to
be no significant difference between the use of three days
or seven days of fluoroquinolone antimicrobials (OR 1.72,
95 % CI 0.71, 4.20, p = 0.23) No patient who received a
carbapenem antimicrobial prophylactically developed sep-
sis following a TRUS biopsy.
Discussion
In this study, we found that the rate of post-biopsy sep-
sis was 1.5 % across the five-year study period. This is
consistent with the intervention arms of the original
clinical trials supporting prophylaxis [4], and may re-
flect relatively low rates of fluoroquinolone resistance
in Australia [28]. This is in contrast to studies in North
America that have demonstrated a rising rate of post-
biopsy sepsis most likely attributable to increasing bac-
terial resistance [8, 9]. In addition we found that a third
of septic patients had evidence of significant organ dys-
function, consistent with severe sepsis, although we did
not observe any mortality. This is in line with previous
studies suggesting the mortality from prostate biopsy is
low [8, 9].
As in similar studies, E. coli was the predominant
causative organism in our series, accounting for 95 % of
positive cultures [13, 25, 29, 30]. A concerning trend has
been the development and spread of genes providing re-
sistance to beta-lactams, quinolones and aminoglycoside
antimicrobials [31]. Fluoroquinolone resistance has been
linked to failure of prophylaxis in previous studies [16,
17]. Notably in our series, 68 % and 59 % of break-
through blood culture isolates were resistant to fluoro-
quinolones and gentamicin respectively. However, we
found that only a third of cases received an ineffective
prophylaxis regimen, based on resistance patterns of








Aminoglycosides Gentamicin 15 (53.6) 20 (58.8)
Tobramycin 3 (10.7) 14 (41.2)
Cephalosporins Cefepime 0 4 (11.7)
Ceftriaxone 4 (14.3) 6 (17.6)
Cephalexin or
Cephazolin
8 (28.6) 12 (35.2)
Carbapenems Imipenem 0 0
Fluoroquinolone Ciprofloxacin or
Norfloxacin
22 (78.6) 23 (67.6)
Nitrofurans Nitrofurantoin 2 (7.1) 0
Penicillins Ampicillin or
Amoxycillin
18 (64.3) 24 (70.6)
Amoxycillin/clavulanic
acid
8 (28.6) 20 (58.8)
Piperacillin 3 (10.7) 10 (29.4)
Ticarcillin/clavulanate 6 (21.4) 8 (23.5)
Sulfonamides Trimethoprim 17 (60.7) 2 (5.9)
Trimethoprim/
sulfamethoxazole
6 (21.4) 11 (32.4)
Total isolate organismsa 28 34
aTotal urine culture organisms: E. coli (n = 27), Acinetobacter spp. (n = 1), Total
blood culture organisms: E. coli (n = 34)
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isolated organisms. This suggests that factors other than
antimicrobial resistance may be responsible for the fail-
ure of prophylaxis, and that switching from fluoroquino-
lones to aminoglycosides may not necessarily be more
effective. The proportion with fluoroquinolone resist-
ance is similar to that found in a New Zealand study
[32] but lower than in North American studies [14].
A wide diversity of antimicrobial prophylaxis regimens
has been reported in the literature [33–37]. This study
identified eight different prophylaxis protocols over the
study period reflecting considerable clinical uncertainty.
The most effective prophylactic regimens include carba-
penem antimicrobials with this study supporting Losco et
al’s finding of a 0 % sepsis rate amongst men undergoing a
TRUS biopsy [38]. Although carbapenem antimicrobials
appear to be highly effective, they can only be administered
Table 2 Risk factors for sepsis
Cases Controls OR (95 % CI) P value
Number 71 213
Patient variables
Age > 65 years 35 (49.3 %) 92 (43.2 %) 1.34 (0.74, 2.40) 0.33
Hospital employee 5 (7.0 %) 13 (6.1 %) 1.16 (0.41, 3.33) 0.78
Autoimmune condition 0 (0 %) 10 (4.5 %) Undefined ND
Immunosuppression 1 (1.4 %) 3 (1.4 %) 1.00 (0.08, 11.93) 1.00
COPD 2 (2.8 %) 4 (1.9 % 1.50 (0.27, 8.19) 0.64
Heart valve replacement 3 (4.2 %) 3 (1.4 %) 3.0 (0.61, 14.86) 0.18
Benign prostate enlargement 14 (19.7 %) 41 (19.2) 1.24 (0.62, 2.43) 0.54
Diabetes 10 (14.1 %) 23 (10.8 %) 1.35 (0.61, 2.96) 0.46
Recent travel 13 (18.3 %) 7 (3.2 %) 5.40 (1.61, 18.09) 0.01
Recent antimicrobial use 7 (9.8 %) 3 (1.4 %) 9.59 (1.97, 46.62) 0.01
Recent hospitalisation 1 (1.4 %) 0 (0.0 %) Undefined ND
Procedural variables
Use of FQ prophylaxis 70 (98.6 %) 213 (100.0 %) Undefined ND
Duration of FQ prophylaxis <7 days 10 (14.1 %) 44 (20.7 %) 1.72 (0.71, 4.20) 0.23
Use of aminoglycoside prophylaxis 19 (26.8 %) 43 (20.2 %) 1.85 (0.81, 4.24) 0.14
Use of a penicillin as prophylaxis 19 (26.8 %) 76 (35.7 %) 0.42 (0.18, 0.98) 0.05
Use of carbapenem as prophylaxis 0 21 (9.8 %) Undefined ND
Previous biopsy 12 (16.9 %) 36 (16.9 %) 1.29 (0.62, 2.70) 0.50
Previous biopsy within 3 years 11 (15.5 %) 26 (12.2 %) 1.31 (0.61, 2.83) 0.48
Urinary catheter 0 (0 %) 0 (0 %) Undefined ND
Preoperative urine culture 1 (1.4 %) 0 (0 %) Undefined ND
Use of enema 31 (43.6 %) 110 (51.6 %) 0.71 (0.30, 1.69) 0.44
Prostate volume >30 mL 53 (74.6 %) 174 (81.7 %) 1.38 (0.64, 2.93) 0.41
PSA > 4 mmol 55 (77.4 %) 168 (78.8 %) Undefined ND
Number of biopsy cores >12 46 (64.8 %) 156 (73.2 %) 0.37 (0.14, 0.95) 0.04
Prostate cancer 42 (59.2 %) 123 (57.7 %) 1.15 (0.63, 2.07) 0.65
ND not done
Table 3 Prophylactic antimicrobial regimens used
Antimicrobial classa # Cases (%) # Controls (%)
F 28 (39.4) 88 (41.3)
F + P 18 (25.3) 63 (29.5)
F + P + A 1 (1.4) 4 (1.8)
F + A 23 (32.3) 37 (17.3)
F + P + C 0 (0) 8 (3.7)
F + P + A + C 0 (0) 1 (0.4)
F + C 0 (0) 11 (5.1)
C + A + CE 0 (0) 1 (0.4)
Unknown 1 (1.4) 0 (0)
Total 71 213
aF fluoroquinolone, P penicillin, A aminoglycoside, C carbapenem, CE cephalosporin
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parenterally, and there is concern that widespread use may
result in the development and spread of carbapenem-
resistant Enterobacteriaceae (CRE) [38, 39]. Other strat-
egies to minimize risk include the use of alternative
prophylactic agents (e.g. nitrofurantoin and/or fosfomycin),
[40, 41] the use of targeted prophylaxis based on microbio-
logical screening for resistance, or alternative surgical ap-
proaches, such as transperineal biopsy.
Consistent with other reports, we found that inter-
national travel in the six months prior to the procedure
was associated with post-biopsy sepsis. Although this
association may be over-estimated due to recall bias, it
is known that the prevalence of fluoroquinolone-
resistance organisms varies around the world [28], that
travel is associated with carriage of antimicrobial resist-
ant bowel flora [21] and that travel to countries with
high fluoroquinolone-resistance has been shown to be a
risk factor for developing sepsis following TRUS biopsy
[20, 42]. Interestingly, we found that all patients who
developed sepsis and travelled internationally had jour-
neyed to the South-East Asia or Western Pacific re-
gions. This may suggest that the risk profile of the
destination may be useful in assessing risk, and help
identify a group where alternative strategies or anti-
microbial agents may be warranted.
This study had a number of limitations. In this ob-
servational study, we cannot exclude the possibility of
unmeasured confounders. This was particularly the
case as a large number of different prophylaxis regi-
mens were used, with little or no documentation about
the rationale for the choices of agents. We attempted
to minimize selection bias by selecting cases and con-
trols from the same population in a systematic manner.
Recall bias may be present due to cases being more
thoroughly questioned about risk factors than controls.
This was true for travel history, with recorded re-
sponses for 51 % of cases and 16 % of controls. Con-
versely patients were more thoroughly questioned
about recent antimicrobial use, with recorded re-
sponses for 73 % of cases and 92 % of controls. It is
possible that patients who underwent TRUS biopsy at
participating hospitals presented with infections else-
where, although routine advice was given to patients to
represent to Cabrini Hospital if complications devel-
oped as it is the only private hospital in this region
with an emergency department. In addition the use of
coding to identify cases is subject to inherent error in
data capture and relevant patients may have conse-
quently been missed. The absence of positive clinical
isolates for all septic patients reflects the sensitivity of
cultures as well as the use of prior antibiotics. The as-
sociation between a higher number of cores and re-
duced sepsis is difficult to explain and is likely to
reflect confounding by unknown factors.
Conclusion
In this study TRUS biopsy sepsis was found to inflict a sig-
nificant impact on patients and the healthcare system. A
wide variety of different prophylaxis regimens and bowel
preparation routines were recorded. Procedural variables
such as extended prophylaxis regimens and the use of an
enema did not show added benefit and may therefore be
superfluous. This study also identified recent international
travel and recent antimicrobial use as risk factors that
were associated with sepsis. Patients with these factors
may represent a better target population for intervention
with alternative preventative strategies. These options in-
clude augmented prophylaxis, tailored prophylaxis or the
transperineal biopy approach.
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